NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for MDCK Cells (Kidney Cells, CCL-34)
- A biodegradable polymer based transfection reagent – once inside the cell, the polymer degrades into smaller less toxic components reducing cell toxicity, facilitating release of the transgene, and improving transfection efficiency
High transfection efficiency of both siRNA and plasmid DNA without compromising cell viability
Achieve robust siRNA uptake for dependable gene silencing
Effective transfection under conditions of up to 40% serum
Transfection kit includes Transfection Enhancer reagent
- Download PowerPoint presentation for MDCK cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 73% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems MDCK Transfection Protocol: [PDF]
Download MSDS: [PDF]
MDCK Cell Line:
The MDCK cell line was established in 1958 from the kidney cells of a perfectly healthy cocker spaniel (Canis familiaris). These cells exhibit epithelial morphology, and are positively tested for keratin. They are useful for processing of beta amyloid precursor protein and its products. MDCK cells are susceptible to viral infection, but make good transfection host. They could be useful for studying kidney cells function and gene expression for biomedical research purposes.
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into MDCK cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A/C in MDCK cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into MDCK cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides pre-optimized transfection kits and electroporation products for life sciences and cancer research. Transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits (animal transfection): 1) Tissue-targeted reagents (delivery of proteins, DNA, and RNA into liver, pancreas, or kidney tissues), and 2) Broad range in vivo biodistribution reagents (PEG-Liposome based reagent, Nanoparticle-based in vivo reagent, Lipid-based transfection kit, and Polymer-based kit). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, mRNA, shRNA, siRNA, and other negatively charged biomolecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6845)
- 1.5 ml (Catalog #6846)
- 8.0 ml (Catalog #7061)